Prelude Therapeutics Income Statement (2019-2026) | PRLD

Income Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue (Quarter)
3.00M4.00M6.50M5.64M4.58M5.70M
Operating items
Research & Development (Quarter)
22.72M25.18M22.82M21.31M22.89M25.87M21.83M24.97M26.26M30.33M27.41M29.51M29.46M31.62M28.82M25.78M21.71M17.99M13.60M16.13M
Selling, General & Administrative (Quarter)
8.12M7.83M7.47M8.15M7.52M7.52M7.28M7.43M7.12M7.05M6.93M7.66M7.92M6.21M5.79M6.41M5.21M5.00M5.16M5.03M
Operating Expenses (Quarter)
30.84M33.01M30.29M29.46M30.41M33.38M29.11M32.40M33.38M37.38M34.34M37.16M37.38M37.83M34.61M32.19M26.92M22.99M18.76M21.16M
Operating Income (Quarter)
-30.84M-33.01M-30.29M-29.46M-30.41M-33.38M-29.11M-32.40M-33.38M-37.38M-34.34M-37.16M-34.38M-33.83M-34.61M-32.19M-20.42M-17.35M-14.18M-15.45M
EBIT (Quarter)
-30.84M-33.01M-30.29M-29.46M-30.41M-33.38M-29.11M-32.40M-33.38M-37.38M-34.34M-37.16M-34.38M-33.83M-34.61M-32.19M-20.42M-17.35M-14.18M-15.45M
Non-operating items
Other Non Operating Income (Quarter)
0.15M0.17M0.82M2.09M0.45M4.74M1.40M1.97M2.78M4.30M2.91M2.42M2.10M5.10M2.52M0.96M0.69M0.89M3.79M1.53M
Net income details
EBT (Quarter)
-170.14M-108.38M-41.59M-37.16M-42.51M-144.44M-38.22M-37.80M-35.98M-37.86M-77.64M-79.85M-76.48M-34.36M-57.55M-54.47M-42.02M-18.08M-34.44M-52.71M
Profit After Tax (Quarter)
-30.86M-32.84M-29.46M-27.37M-30.03M-27.97M-27.72M-30.43M-30.61M-32.25M-31.43M-34.74M-32.27M-28.92M-32.11M-31.23M-19.73M-16.42M-10.43M-14.11M
Income from Continuing Operations (Quarter)
-170.14M-108.38M-41.59M-37.16M-42.51M-144.44M-38.22M-37.80M-35.98M-37.86M-77.64M-79.85M-76.48M-34.36M-57.55M-54.47M-42.02M-18.08M-34.44M-52.71M
Consolidated Net Income (Quarter)
-170.14M-108.38M-41.59M-37.16M-42.51M-144.44M-38.22M-37.80M-35.98M-37.86M-77.64M-79.85M-76.48M-34.36M-57.55M-54.47M-42.02M-18.08M-34.44M-52.71M
Income towards Parent Company (Quarter)
-170.14M-108.38M-41.59M-37.16M-42.51M-144.44M-38.22M-37.80M-35.98M-37.86M-77.64M-79.85M-76.48M-34.36M-57.55M-54.47M-42.02M-18.08M-34.44M-52.71M
Net Income towards Common Stockholders (Quarter)
-170.14M-108.38M-41.59M-37.16M-42.51M-144.44M-38.22M-37.80M-35.98M-37.86M-77.64M-79.85M-76.48M-34.36M-57.55M-54.47M-42.02M-18.08M-34.44M-52.71M
Additional items
EPS (Basic) (Quarter)
-3.67-2.35-0.88-0.79-0.90-3.05-0.80-0.67-0.53-0.63-1.03-1.05-1.01-0.45-0.76-0.72-0.55-0.23-0.42-0.54
EPS (Diluted) (Quarter)
-3.67-2.35-0.88-0.79-0.90-3.05-0.80-0.67-0.53-0.63-1.03-1.05-1.01-0.45-0.76-0.72-0.55-0.23-0.42-0.54
Shares Outstanding (Quarter)
46.33M46.05M47.07M47.28M47.45M47.37M47.74M56.24M67.64M60.36M75.74M75.76M75.86M75.81M75.99M75.99M76.13M76.96M82.52M98.39M
Shares Outstanding (Diluted) (Quarter)
46.33M46.05M47.07M47.28M47.45M47.37M47.74M56.24M67.64M60.36M75.74M75.76M75.86M75.81M75.99M75.99M76.13M76.96M82.52M98.39M
Shares Outstanding (Entity) (Quarter)
46.33M46.05M47.07M47.28M47.45M47.37M47.74M56.24M67.64M60.36M75.74M75.76M75.86M75.81M75.99M75.99M76.13M76.96M82.52M79.80M
EBITDA (Quarter)
-30.84M-33.01M-30.29M-29.46M-30.41M-33.38M-29.11M-32.40M-33.38M-37.38M-34.34M-37.16M-34.38M-33.83M-34.61M-32.19M-20.42M-17.35M-14.18M-15.45M
Interest Expenses (Quarter)
139.30M75.37M11.30M7.70M12.10M111.05M9.10M5.40M2.60M0.48M43.29M42.69M42.11M0.53M22.94M22.27M21.60M0.73M20.27M37.25M